Cure disease – Heiki Thu, 22 Jul 2021 19:08:32 +0000 en-US hourly 1 Cure disease – Heiki 32 32 Improvement in survival not demonstrated with adjuvant chemotherapy in locally advanced cervical cancer Thu, 22 Jul 2021 18:06:58 +0000

The final analysis revealed that despite the additional cycles of chemotherapy, OS at 5 years was the same between the 2 groups. The OS at 5 years for chemotherapy alone was 71% and 72% for the chemotherapy plus adjuvant chemotherapy group. PFS told a similar story, with PFS for the control group being 61% and 63% for the experimental group. The disease recurrence patterns between the 2 groups were also similar.

In an interview with Targeted oncology, Bradley Monk, MD, FACCOG, FACS, Gynecologist Oncologist at Arizona Oncology and Medical Director of Gynecologic Oncology Research at the US Oncology Network, discusses the OUTBACK trial, including results, strengths and challenges.

Targeted Oncology ™: Can you give a brief overview of the OUTBACK trial?

MONK: I have a passion for trying to help women who develop cervical cancer. I understand that this is a disease that should be avoided with HPV vaccination, PAP test and HPV cervical virus test. I think we all know this is not going the way we would like and that there are still women, even in this country, who are struggling and even dying from cervical cancer. At the 2021 American Society of Clinical Oncology Annual Meeting Plenary Session, the OUTBACK trial was presented. This study examined adjuvant chemotherapy after chemoradiation as the primary treatment for locally advanced cervical cancer compared to chemoradiation alone. This was a collaborative trial between the Australian New Zealand Gynecologic Oncology Group, Radiation Therapy Oncology Group and NRG Oncology. At the time the study was developed, I was chair of the NRG’s Cervical Cancer Committee, a position I held for 11 years.

Can you explain the design of the study?

In 1999, the National Cancer Institute issued a clinical alert, saying that weekly chemotherapy of cisplatin should be added to radiation therapy in the treatment of locally advanced cervical cancer and in 1999, became the clinical standard. In the context of recurrence, cervical cancer was historically considered resistant to chemotherapy. Also through the Historical Group of Gynecological Oncology, which has become the NRG Oncology Group, we have shown that chemotherapy is very sensitive and on behalf of NRG Oncology, I published in 2009, in the Journal of Clinical Oncology a study called Protocol 204 (NCT03438396), which established comprehensive systemic therapy for cervical cancer in the setting of a recurrence as a cisplatin or carboplatin platinum taxane with paclitaxel.

With this new discovery, we decided to launch a very ambitious randomized phase 3 trial involving patients with locally advanced cervical cancer treated with radiotherapy and randomizing them on a 1: 1 to 4 basis. Additional cycles of carboplatin, paclitaxel, delivered in an area under the curve of 5, and paclitaxel at 155 milligrams per square meter. This was a bit unusual dose because these patients had all received previous radiation therapy, which increases the toxicity of the cytotoxic chemotherapy. It was a very ambitious trial. The study was originally scheduled to include 780 patients and was scaled up to 900 and had 80% power with 5% bilateral alpha for an 8% absolute improvement in OS.

While this trial was ongoing, in 2013 a study was presented to ASCO and we obtained FDA approval for the addition of bevacizumab (Avastin) to the use of taxane-based chemotherapy. platinum in recurrent cervical cancer. He changed the standard of care while the standard was in progress. Recently, we also had 2 Phase 3 trials of checkpoint inhibitors that advanced the standard of care.

That said, this trial reported to ASCO 2021 showed that there was no difference when 4 more cycles of carboplatin and paclitaxel were added to chemotherapy. There was no difference in OS at 5 years, which in the radiotherapy alone group was 71%.

When there were 4 additional cycles of carboplatin and paclitaxel after chemotherapy and radiotherapy, the 5-year survival was 1% greater with a relative risk of 0.90 and a confidence interval of 0.70 overlapping 1 with a cut-off greater than 1.17.

Interestingly, there was also no improvement in PFS. The 5-year PFS was 61% versus 63%. There has also been no improvement in local regional control. There has been a slight numerical improvement in local control, but not in a substantial way. If anything, as we looked at the subset analysis, which generated assumptions, patients over 60 did better without the chemotherapy additions. So, by looking at the important prognostic factors, not only were we unable to identify the subset where it was working, but we actually identified a subset where it appeared not to be working.

Can you explain the rationale behind adding these extra rounds of chemotherapy to this treatment plan?

The OUTBACK trial identified a group of patients at high risk of recurrence, meaning the tumors were too large for radical surgery, the hypothesis being that chemotherapy might improve OS and possibly the cure rate by cytotoxic destruction of micrometastatic disease.

What impact do you think these results will have on the clinical or community oncology environment?

We have seen the evolution that cervical cancer is indeed sensitive to chemotherapy. NRG Oncology and the Historical Gynecologic Oncology Group have played a very important role in defining the role of radiation in the systemic therapy and treatment of cervical cancer, especially locally advanced cervical cancer. This is a wonderful opportunity to improve on this result, especially with the discovery over the last decade or so that cervical cancer is in fact a disease sensitive to chemotherapy, rather than a disease resistant to chemotherapy. chemotherapy. For this reason, these dates had an impact because they show that this is not the case.

There are well-meaning providers who administer additional cycles of chemotherapy after chemotherapy and radiation therapy in locally advanced cervical cancer with no evidence. It must stop because it does not bring any benefit. This is the impact of this research.

There are 4 lessons to be learned from the OUTBACK trial. And we should use these lessons to improve the quality of our ongoing and future clinical trials and locally advanced cervical cancer. Number 1, when post-progression survival is long and crossbreeding is common, or switching as we call it, the endpoint should never be OS. It should be PFS. Turns out it probably wouldn’t have been positive anyway.

The second lesson is that you have to use the right agents at this time. The good agents back then were carboplatin / paclitaxel, but as I mentioned in 2014, bevacizumab and carboplatin / paclitaxel have become the global standard. And today we have 2 randomized phase 3 trials of checkpoint inhibitors.

Third, we need to register the right patients. These patients who were recruited were in fact not at high risk of recurrence, most of them were cured. So we need to identify the patients with the highest unmet medical need, register those patients with the right endpoint, and treat them with the right agents.

Finally, patients who receive radiotherapy and chemotherapy are quite rough at the end of their treatment. Twenty percent of patients, in fact, have not even completed their chemotherapy and radiation therapy. If you don’t complete it, you’re definitely not going to move into a maintenance phase. Even when they finished it, about 20% did not move on to a maintenance phase. So if we want to change the impact of chemotherapy and radiotherapy, this idea of ​​a strategy of sustaining the change after chemotherapy and radiotherapy, is probably not a good idea. It may be best to start systemic therapy during radiation therapy, which after all is the start of systemic cisplatin therapy.

Mileskin LR, Moore KN, Barnes E, et al. Adjuvant chemotherapy after radiochemotherapy as primary treatment for locally advanced cervical cancer compared to radiochemotherapy alone: ​​the randomized phase III trial OUTBACK (ANZGOG 0902, RTOG 1174, NRG 0274). J Clin Oncol. 39 (18): L8A3. doi: 10.1200 / JCO.2021.39.15_suppl.LBA3.

Source link

]]> 0
Use caution when talking to someone with a chronic illness Wed, 21 Jul 2021 14:01:06 +0000

When you talk to someone with a chronic illness, you can do and say things with the best of intentions, but sometimes it can not translate well. Here are some of the things I don’t like to hear.


Sometimes when I tell someone I have sickle cell anemia, they instantly apologize. I don’t think this is the best answer.

For me, apologize to someone with a chronic condition it is like assuming that they are suffering because of their health. Things might not be amazing when it comes to dealing with sickle cell disease, but I love my life regardless, and I love all of the things that make me who I am.

I know people whose chronic illnesses develop later in life. In these situations, they often mourn their past healthier lives. Although I sympathize, I cannot sympathize.

recommended reading

Sickle cell disease is a genetic condition, and those of us who have it experience it from birth. Life with sickle cell disease is all I’ve known, and I’ve learned to thrive with it all my life. When people apologize to me for not living a normal life, I feel quite uncomfortable and never know how to react.

Treatment recommendations

Due to the platforms I have and my willingness to be so open about my health, many people – including complete strangers – send me messages urging me to consider a bone marrow / cell transplant. strain to help treat my sickle cell anemia. Again, I know people are well-meaning in suggesting that I go through this procedure, but it’s not something I don’t like to discuss, and I currently have no intention of having the procedure done. at least not yet.

I can assure you that no one is better informed about their options than someone with a chronic illness. If there is anything that could potentially cure us of our disease, trust me that we have done our due diligence, considered all of our options, and made an informed decision. If this decision is to live your life while managing the disease instead of undergoing treatment, please believe there is a good reason!

I consider myself very lucky with my health. I’m doing a decent job of minimizing the number of sickle cell symptoms I experience, and the idea of ​​having a stem cell transplant seems too risky right now.

We don’t talk as much about health issues as we would like. Due to a lack of awareness of certain conditions, people who are not affected by a chronic disease do not know the best ways to interact with people with these conditions.

Hopefully this column has provided some insight into the best ways to interact with people with health issues. If you have a chronic illness, what don’t you like to hear? Please share in the comments below.


To note: News about sickle cell anemia is strictly a disease news and information site. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your doctor or other qualified healthcare professional with any questions you may have regarding a health problem. Never disregard the advice of a medical professional and do not delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of News about sickle cell anemia or its parent company, BioNews, and aim to spark discussion about issues related to sickle cell anemia.

Source link

]]> 0
Targeting Piezo1 Protein May Be An Ideal New Strategy To Cure Multiple Sclerosis Wed, 21 Jul 2021 01:31:00 +0000

In a new study from the University of California, Irvine, researchers found that a certain protein prevented regulatory T cells (Tregs) from doing their job effectively in controlling the damaging effects of inflammation in a model of sclerosis plaque (MS), a devastating autoimmune disease. nervous system disease.

Posted this month in Scientists progress, the new study highlights the important role of Piezo1, a specialized protein called the ion channel, in the immunity and function of T cells linked to autoimmune neuro-inflammatory disorders.

We found that Piezo1 selectively retains Treg cells, limiting their potential to attenuate autoimmune neuroinflammation. Genetic suppression of Piezo1 in transgenic mice resulted in an enlarged pool of Treg cells, which were more able to effectively reduce neuroinflammation and with it the severity of disease. “

Michael D. Cahalan, PhD, Emeritus Professor and Chairman, Department of Physiology and Biophysics, UCI Faculty of Medicine

T cells rely on specialized proteins, such as Piezo1, to detect and respond to a variety of diseases and conditions, including bacterial infections, wound healing, and even cancer. The uncontrolled activity of T cells, however, can give rise to autoimmune disorders in which the immune system attacks normal cells in the body. Tregs constantly heal immune responses and play an essential role in preventing autoimmunity.

“Given the demonstrated ability of Piezo1 to retain Treg cells, we believe that inhibition of Piezo1 could lead to new treatments for neuro-inflammatory disorders, such as MS,” explained Amit Jairaman, PhD, and Shivashankar Othy, PhD, principal authors of the study, both from the scientific project of the department of physiology and biophysics.

Piezo1 conducts ions when cells are subjected to mechanical forces. Research over the past decade has shed light on the role of Piezo1 in the regulation of vital physiological functions, including red blood cell volume (RBC), blood pressure, vascular development, bone formation, and cell differentiation. neural strains. However, its role in modulating the immune response has not been appreciated before. And, while calcium-conducting ion channels, like Piezo1, were known to direct various aspects of T cell function, researchers were surprised to find that Piezo1 was not essential for a host of cell functions. T cells that depend on calcium, such as lymph nodes. homing, interstitial motility, activation, proliferation or differentiation into effector T cells.

“We found that the role of Piezo1 appears to be quite specific to Tregs. Therefore, targeting Piezo1 could be an ideal new strategy for curing MS while preserving the ability of the immune system to fight new infections,” added Othy, whose research lasted 12 years. focused on finding ways to harness the therapeutic potential of Treg cells.

Further study of the function of Piezo1 is needed to understand the therapeutic potential and better understand the processes by which cells sense and respond to mechanical stimuli during immune responses.


Journal reference:

Jairman, A., et al. (2021) Piezo1 channels restrict regulatory T cells but are essential for effector CD4 + T cell responses. Scientists progress.

Source link

]]> 0
Be Pragmatic, Says Manipur to Erendro’s Plea for Compensation Before the Supreme Court | Latest India News Tue, 20 Jul 2021 15:14:35 +0000

NEW DELHI: Manipur activist Leichombam Erendro’s father on Tuesday asked the Supreme Court to order compensation for the activist who spent more than two months in prison for a Facebook post.

Bench of Judges DY Chandrachud and MR Shah, who ordered Leichombam Erendro’s immediate release on Monday, requested the Manipur government’s written response to the compensation claim.

At Tuesday’s hearing, Solicitor General Tushar Mehta, who appeared for Manipur, told the Supreme Court that Erendro was released on Monday and that the case against him under strict security law national had been canceled.

It should stop there, and the petitioner should take a pragmatic approach in acknowledging that the relief has been granted, Tushar Mehta said.

The court said the petitioner chose to seek redress in court and gave the state two weeks to file its response. The next hearing is scheduled for August 6.

Appearing for Erendro’s father, L Raghumani Singh, lawyer Shadan Farasat told the Supreme Court that five cases had been filed against his son since 2017 and that the state had not filed an indictment in a single case.

The bench said it was “serious business” that Erendro had “lost his freedom since May”.

Leichombam Erendro was arrested on May 13 this year for his Facebook post that said cow dung and urine is not a cure for coronavirus disease because its cure is scientific and common sense. This message follows the death of the president of the Bharatiya Janata Party (BJP), Tikendra Singh. He was arrested after local BJP leaders filed a complaint against the social media post.

In the petition, Erendro’s father said his son’s statement was made in the context of the death of the president of the Manipur BJP due to Covid-19, “as a criticism of the unscientific position taken and misinformation disseminated by several BJP politicians regarding cow urine and cow dung being effective in preventing / treating Covid-19. ”He said the post was deleted shortly after it was posted on May 13 .

“This case is a shocking case of the misuse of the pre-trial detention law to hush up completely innocuous speech that is fully constitutionally protected and has been delivered in the public interest,” the petition said.

Source link

]]> 0
Gene therapy in early stages of Huntington’s disease may slow progression of symptoms Wed, 07 Jul 2021 13:01:31 +0000 PICTURE: Representative maps of cerebral blood volume in mouse brains of the genotypes and treatment groups indicated. The top row shows the raw images – the red regions of interest indicate the quantified view of the brain … After Credit: Wenzhen Duan, MD, Ph.D. In a new study in mice, researchers at Johns Hopkins Medicine […]]]>

PICTURE: Representative maps of cerebral blood volume in mouse brains of the genotypes and treatment groups indicated. The top row shows the raw images – the red regions of interest indicate the quantified view of the brain … After

Credit: Wenzhen Duan, MD, Ph.D.

In a new study in mice, researchers at Johns Hopkins Medicine report that using MRI scans to measure blood volume in the brain may serve as a non-invasive way to potentially track the progress of gene-editing therapies for early-stage Huntington’s disease, a neurodegenerative disease that attacks brain cells. Researchers say that identifying and treating the mutation known to cause Huntington’s disease with this type of gene therapy, before a patient starts showing symptoms, can slow the progression of the disease.

the results of the study were published on May 27 in the journal Brain.

“What is exciting about this study is the opportunity to identify a reliable biomarker that can track the potential success of genetic therapies before patients start showing symptoms,” says Wenzhen Duan, MD, Ph.D., Director of the Translational Neurobiology Laboratory and Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. “Such a biomarker could facilitate the development of new treatments and help us determine the best time to start them.”

Huntington’s disease is a rare genetic disorder caused by a single defective gene, nicknamed “huntingtin”, on human chromosome 4. The gene is passed from parents to children – if one parent has the mutation, each child has a 50% chance to inherit it. Huntington’s disease is incurable and can lead to emotional disturbances, loss of intellectual capacity, and uncontrolled movement. Through genetic testing, people can find out if they have the disease long before symptoms appear, which usually happens in their 40s or 50s.

For the study, Duan and his team collaborated with colleagues from Kennedy Krieger Institute in Baltimore, Maryland, which developed a new method to more accurately measure blood volume in the brain using advanced functional MRI scans. With the scans, they can map the path of blood flow through small blood vessels called arterioles in the brains of mice designed to carry the mutation in the human huntingtin gene that reflects the early stages of Huntington’s disease in humans.

Duan notes that there are many known metabolic changes in the brains of people with Huntington’s disease, and that these changes initiate a cerebral blood volume response in the early stages of the disease. Blood volume is a key marker of oxygen delivery to brain cells, which in turn provides the energy for neurons to function. But with Huntington’s disease, the arteriolar blood volume in the brain is drastically reduced, causing neurons to deteriorate due to lack of oxygen as the disease progresses.

In a series of experiments, the researchers removed the mutation in the huntingtin gene in mice, using a gene-editing technology known as CRISPR – a genome-editing tool that enables the alteration of a DNA sequence to alter the function of genes. Then they used the MRI imaging technique and other tests to track brain function over time both in mice with the huntingtin mutation, in which they deleted the faulty genetic sequence, and in mice with the huntingtin mutation. a control group of mice in which the defective gene had not been modified.

The experiments evaluated abnormalities in the trajectory of arteriolar blood volumes in the brain of mice with the Huntington’s disease mutation at 3, 6 and 9 months (pre-symptom stage, onset of symptoms and post-symptom stage, respectively) . The researchers investigated whether deleting the mutant huntingtin gene in neurons could normalize altered arteriolar blood volumes in the pre-symptom stage, and whether reduced expression of the huntingtin gene in the pre-symptomatic stage could delay or even prevent it. development of symptoms.

“Overall, our data suggest that measuring cerebral arteriolar blood volume may be a promising non-invasive biomarker for testing new therapies in patients with Huntington’s disease who have not yet shown symptoms of the disease. “said Duan. “Introducing treatment at this early stage can have long-term benefits.”

When the researchers mapped the trajectory of cerebral blood volume and performed an assortment of brain and motor tests in the mice at 3 months of age, and compared the test to those in the control group, they found no significant difference, except in cerebral blood volumes. However, Huntington’s symptoms in mice carrying the huntingtin gene began at 6 months of age and gradually worsened at 9 months, suggesting that an alteration in cerebral blood volume occurs before motor symptoms and brain cell atrophy – typical features of the disease.

The changes in cerebral blood volume were also found to be similar to those seen in patients with Huntington’s disease before they began to show symptoms, which diminish with the onset of symptoms and as the disease progresses over time. time.

The researchers also analyzed the structure of arteriole blood vessels in the brains of mice carrying the mutant huntingtin gene at 3 and 9 months and found no difference in the number of vessel segments at the pre-symptomatic stage. However, they observed that the smaller blood vessels had increased density and reduced diameter, which may be a vascular response to compensate for impaired neuronal brain function. This could suggest, the researchers conclude, that an alteration in vascular structure leads to decreased arteriole blood volumes and possibly a compromised ability to compensate for symptom-stage loss.

Considering that the symptoms of Huntington’s disease depend not only on the loss of brain cells, but also on the deterioration of neurons, the researchers set out to determine whether suppressing the huntingtin gene at the pre-symptomatic stage in mice could. delay or even prevent the progression of the disease. To do this, the researchers introduced the altered huntingtin gene into the neurons of mice at the age of 2 months and evaluated the results at the age of 3 months (in the absence of atrophy or motor deficit ).

Remarkably, according to the researchers, the cerebral arteriolar blood volume in mice with the altered huntingtin gene was This suggests that the altered cerebral blood volume during the pre-symptomatic phase in mice is most likely due to neuronal changes in activity or metabolism.

“Our results demonstrate that significant changes in arteriolar cerebral blood volumes occur before neurons begin to degenerate and symptoms begin, which reinforces the idea that impaired cerebrovascular function is an early symptom of Huntington’s disease, ”says Duan. She explains that these changes also indicate that there is a pre-symptom therapeutic window in which to test interventions. Although no animal model replicates all of the symptoms of human Huntington’s disease, this research offers an alternative system to study functional changes in the pre-symptom stage, she says.

Further validation of these results in human clinical trials would facilitate the development of effective therapeutic interventions for patients with Huntington’s disease before they start to develop symptoms. “The goal is to delay or even completely prevent the onset of Huntington’s disease,” says Duan.

Along with Duan, other researchers who have contributed to the work are Hongshuai Liu, Chuangchuang Zhang, Jing Jin, Liam Cheng, Qian Wu, Zhiliang Wei, Peiying Liu and Christopher Ross of Johns Hopkins, and Jiadi Xu, Xinyuan Miao, Hanzhang Lu, Peter van Zijl and Jun Hua of the Kennedy Krieger Institute and Johns Hopkins.


Source link

]]> 0
World Multiple Sclerosis Day 2021: Know the Symptoms, Risks and Treatment of Multiple Sclerosis Sun, 30 May 2021 09:21:45 +0000 World Multiple Sclerosis Day 2021: Know the Symptoms, Risks and Treatment of Multiple Sclerosis | Photo credit: Pixabay & nbsp Highlights May 30 is celebrated as World Multiple Sclerosis Day According to the National Multiple Sclerosis Society, approximately 2.3 million people worldwide have multiple sclerosis So far there is no cure for multiple sclerosis, but […]]]>

World Multiple Sclerosis Day 2021: Know the Symptoms, Risks and Treatment of Multiple Sclerosis | Photo credit: Pixabay & nbsp


  • May 30 is celebrated as World Multiple Sclerosis Day
  • According to the National Multiple Sclerosis Society, approximately 2.3 million people worldwide have multiple sclerosis
  • So far there is no cure for multiple sclerosis, but treatments can help relieve symptoms

New Delhi: May 30 is celebrated annually as World Multiple Sclerosis Day. This day aims to inform and educate people about this chronic disease to help people with this disease to coexist happily and peacefully in the world. According to the National Multiple Sclerosis Society, approximately 2.3 million people worldwide have multiple sclerosis. Multiple sclerosis is a neurological disorder that affects the central nervous system (CNS). Clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS) are the types of multiple sclerosis.

Multiple Sclerosis – Symptoms, Causes and Risk Factors

The common symptoms of multiple sclerosis are as follows:

  • Weak muscles
  • A tingling or numb feeling in certain parts of the body
  • Lhermitte’s sign
  • Tired
  • Vertigo and lightheadedness
  • Reduced libido or libido
  • Intestinal problems
  • Muscle spasms and pain
  • Vision compromised
  • Cognitive decline

Common causes and risk factors that can contribute to the development of multiple sclerosis are as follows:

  1. Contraction of infections such as mononucleosis, Epstein Barr virus and mycoplasma pneumonia.
  2. Smokers have a higher risk of developing MS than non-smokers.
  3. Genetics can also be a risk factor.
  4. Vitamin deficiency such as vitamin B12 or D deficiency.
  5. People between the ages of 20 and 40 and women are at greater risk of developing MS.

Multiple Sclerosis – Diagnosis and Treatment

Multiple sclerosis is a neurological disease, so diagnostic methods include cerebrospinal fluid testing, MRI scans, and evoked potential testing. There is no cure for multiple sclerosis, but methods to relieve the symptoms and slow the progression are followed by doctors for treatment. Medication, stem cell therapy, rehabilitation, plasma therapy, and physiotherapy are common parts of treatment. Medical marijuana is also often used to relieve pain and stiffness, however, it should be noted that medical marijuana is not the same as street marijuana.

Disclaimer: The tips and suggestions mentioned in the article are provided for informational purposes only and should not be construed as professional medical advice. Always consult your doctor or dietitian before starting a fitness program or making any changes to your diet.

Source link

]]> 0
Andhra man in viral video vouches for Brinjal-based ‘COVID Cure’ eye drops now in intensive care Wed, 26 May 2021 05:40:25 +0000 Multiple cases of chemical conjunctivitis have been observed in COVID-19 patients who used the disputed herbal eye drops. Days after video of a COVID-19 patient saying he felt better after taking Krishnapatnam’s controversial herbal treatment in Andhra Pradesh went viral, authorities said he was hospitalized and now undergoing treatment in an intensive care unit with […]]]>

Multiple cases of chemical conjunctivitis have been observed in COVID-19 patients who used the disputed herbal eye drops.

Days after video of a COVID-19 patient saying he felt better after taking Krishnapatnam’s controversial herbal treatment in Andhra Pradesh went viral, authorities said he was hospitalized and now undergoing treatment in an intensive care unit with oxygen. The patient in the video, a retired director from the neighboring Kota mandal district of Nellore, had traveled to Krishnapatnam to try the herbal preparations distributed by a local doctor named Bonigi Anandaiah. In a video widely shared on social media and broadcast by several news channels, Kotaiah, who had arrived from a hospital where he was treated for a week with an oxygen mask, said he felt much better afterwards. have received the eye drops. prepared by Anandaiah.

Kotaiah was one of many similar testimonies attesting to the preparations for Anandaiah that had been widely shared. The eye drops were being administered with claims that they could help increase the drop in blood oxygen levels in critical COVID-19 patients. The drops were made from honey, tail pepper and the pulp of a certain type of brinjal, according to information shared by Anandaiah. Rationalists urged the state government not to allow “treatment” of Krishnapatnam until it has been proven to work, as it would promote belief in unscientific treatments.

Nellore Joint Collector MN Harendhira Prasad said Kotaiah was admitted to hospital on May 23 with a CT severity score of over 20 at the time of admission. According to a doctor familiar with Kotaiah’s condition, he is on oxygen in the intensive care unit with his blood oxygen level fluctuating around 85. The doctor said Kotaiah had complained of irritation and eye redness at the time of hospitalization, and it has been found to have chemical conjunctivitis. He added that several patients who took the herbal treatment continued to be hospitalized because the “cure” failed to relieve their condition. “We saw about 24 COVID-19 patients admitted to the hospital, who had received Anandaiah’s treatment. Some of them complained of eye irritation and consulted an ophthalmologist. A few people seem to instantly feel better after taking the eye drops, but there is a chance of getting chemical conjunctivitis eventually, although individual reactions may vary, ”said the doctor.

With a few people reporting that they felt better after taking the eye drops, and with an improvement in their oxygen levels, the untested herbal concoctions that were given away free by Anandaiah had become very popular. Last week, the distribution was halted by the district authorities, who sent the preparations to be studied in an Ayurveda laboratory. On May 21, distribution resumed with the support of YSRCP MP Kakani Govardhan Reddy despite lack of clearance from district authorities, and tens of thousands of people gathered at the distribution site, violating COVID-protocols. 19. The MLA had defended this decision saying that some patients were seeing good results, on the basis of which many people had developed faith that the “treatment” worked. Officials from the state health department as well as the AYUSH department have so far claimed that the drug does not appear to have any immediate negative effects. “People are concerned that there are long-term side effects. Once it is established that there are no side effects, the distribution will continue, ”said the MP.

Experts and doctors have suggested that patients may have felt better either because of a placebo effect or because of the disease’s natural progression in their bodies. The doctor who was familiar with the condition of patients taking Anandaiah’s preparations said that apart from the possibility of chemical conjunctivitis, patients will need to be monitored more for any long-term side effects.

On May 24, AYUSH State Commissioner Ramulu N said the Central Council for Research in Ayurvedic Studies is conducting a comprehensive test of the herbal remedy by giving it to at least 500 people. “It is necessary to know if the herbal preparations prepared by Anandaiah caused any adverse health effects and a report on this matter could come in about a week,” he said.

Also read:

Andhra ‘COVID Cure’: Why Scientific Evidence Is More Important Than People’s Faith

Authorities to conduct trial of Andhra’s ‘herbal remedy’ for COVID-19 on 500 people

Source link

]]> 0
Garden center raises money for medical research on children Sun, 02 May 2021 07:34:00 +0000 Businesswoman and nature lover Vinny Piscopo tell Daniela allen about the project One of the things that raised the spirits of many during the COVID-19 pandemic has certainly been love and appreciation for nature. At a time when mental health has become more important than ever, experts advise getting out to the countryside and getting […]]]>

Businesswoman and nature lover Vinny Piscopo tell Daniela allen about the project

One of the things that raised the spirits of many during the COVID-19 pandemic has certainly been love and appreciation for nature.

At a time when mental health has become more important than ever, experts advise getting out to the countryside and getting as much fresh air as possible. The absorption of the natural environment and the colors of nature are soothing to the eyes and comforting to the mind.

Yet many of those who did not have access to outdoor space during this difficult time have filled their homes with plants, which can give a sense of hope and a desire to feel freedom again.

At the right time, the Research Innovation and Development Trust (RIDT) at the University of Malta launched a spring initiative, in collaboration with one of Malta’s leading garden centers, to raise funds for research through its Superhero campaign. .

Piscopo Gardens and Pet Shop have adopted the campaign to support research related to medical conditions affecting children. This is happening at a time when the pursuit of quality of life and well-being is at the forefront, as the world increasingly realizes the crucial value of research in curing disease.

People understand what really matters in life. For me it’s family and nature

Nature and life-loving businesswoman Vinny Piscopo is behind this venture and is committed to matching every donation the public makes to the university’s research campaign.

“I love the idea that as Piscopo Gardens we can really help during such times. Research is vital to finding a cure for the ongoing battles that unfortunately many face, ”says Piscopo.

Vinny Piscopo

“Children are our future, if we can protect them and give them better lives, then I believe we are doing something right while we are on this planet.”

Thanks to the Superhero campaign, “my team and I feel that our efforts and our daily work go towards a great cause to help children. Visit us at Piscopo Gardens and donate € 1, € 2 or € 5 and as a business we will match your donation. Anyone can tell the difference. ”

Piscopo Gardens was established in 1994 and has grown steadily since. It has the largest selection of plants on the island, paired with a wide range of gardening products, pet food, and pet supplies.

While running this large company, Piscopo refers to work-life balance and says she’s learned not to let stress take over.

“I relax when I spend time playing with my stepson and taking long walks by the sea or in the countryside.”

She says surrounding yourself with people who love you and make you happy is one of the most important things you can do for yourself.

Referring to the COVID-19 pandemic, she said, “People understand what really matters in life. For me, it’s family and nature. We realized that the many things we might have taken for granted actually help us live better lives. Once these were taken away from us, we appreciated how important they really are.

At work, she and her team strive to educate and teach anyone interested in taking up gardening as a hobby as well as nurturing a love for animals. She adds that it’s a breath of fresh air to be able to be surrounded by nature 24/7.

“A lot of our customers visit us to be able to relax because our environment is really unique, with so many plants in one place,” she says.

With Mother’s Day just around the corner, the garden center is stocked to the brim with many unique and different products.

Visit the Piscopo Gardens Facebook page or their center in Burmarrad, which is open seven days a week. Every purchase made through the end of June will help support the Superhero Campaign for Research on Children.

Independent journalism costs money. Times of Malta support for the price of a coffee.

Support us

Source link

]]> 0
Core One Labs signs definitive agreement to acquire OTC markets from Akome Biotech: CLABF Thu, 29 Apr 2021 08:00:00 +0000 VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company“), A Life Sciences Biotechnology Research & Development Company Focused On Advancing Psychedelic Drugs In The Market, Is Happy To Announce It Has Entered A Definitive Share Purchase Agreement (the”Final agreement”), As of […]]]>

VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company“), A Life Sciences Biotechnology Research & Development Company Focused On Advancing Psychedelic Drugs In The Market, Is Happy To Announce It Has Entered A Definitive Share Purchase Agreement (the”Final agreement”), As of April 23, 2021, pursuant to which it will acquire all of the outstanding share capital of Akome Biotech Ltd. (“Akome”). The Akome acquisition places the company at the forefront of the development of psychedelic drugs for neurological diseases and mental disorders.

Akome CEO, Dr Santiago Ferro has extensive experience leading clinical research teams and has been involved in all aspects of a start-up and the product lifecycle: from product development clinical and regulatory strategies, sales and marketing opportunities with companies such as Sanofi Pasteur, Novartis and Glaxo Smith Klein. Dr Fadia Saad is co-founder of Akome and the inventor of its patents.

Akome’s goal is to develop safe and effective treatments for stroke, Alzheimer’s disease, depression and Parkinson’s disease. 1The global stroke management market was worth $ 22.5 billion in 2016 and is expected to reach $ 36.7 billion by 2023, with a CAGR of 7.1%. 287% of strokes are ischemic strokes. An ischemic stroke occurs when blood flow through the artery that supplies oxygen-rich blood to the brain is blocked. The treatment currently available for acute ischemic stroke is the administration of the thrombolytic agent, tissue plasminogen activator.

3The global Alzheimer’s disease therapeutics market is expected to reach USD 13.57 billion by 2027, up from USD 7.42 billion in 2019, with a substantial CAGR of 9.2% throughout the forecast period . There is currently no pharmacological treatment available today to slow or stop the damage and destruction of neurons responsible for Alzheimer’s disease. No drug has been specifically approved by the FDA to treat the behavioral and psychiatric symptoms that may develop in the moderate and severe stages of Alzheimer’s dementia.

4Depression affects more than 264 million people. It is a disabling disorder, responsible for most of the 800,000 annual suicides. In 2008, the WHO ranked major depression as the third leading cause of the disease burden globally and projected it to be number one by 2030.

5Parkinson’s disease is a global burden and has more than doubled over the past decade. Almost a million people live with Parkinson’s disease in the United States and 10 million people worldwide. The Parkinson’s disease treatment market was valued at $ 3.99 billion in 2016, and by 2022 it is expected to reach $ 5.69 billion. Currently, there is no cure for Parkinson’s disease, but there are therapies available to relieve the symptoms. Levodopa is the main drug used to make dopamine to replenish the brain by decreasing the supply of dopamine mimicking in the brain.

Joel Shacker, CEO of the company, said: “This acquisition will place us at the forefront of research into the use of psychedelics for the treatment of multiple illnesses, elevating our company’s portfolio to be comparable to that of the largest company in the industry. Akome’s seasoned management team has experience taking products from their developmental stage to commercialization. Their current pipeline of four interim composition patents looks forward to expanding into commercial products to help people with Alzheimer’s disease, stroke, Parkinson’s disease and depression, opening us up to to a multi-billion dollar processing market.

In consideration for all of Akome’s outstanding share capital, the Company is required to issue 3,500,000 common shares to existing Akome shareholders. After issuance, the shares will be subject to the conditions of a pooling agreement, during which they cannot be transferred or traded without the prior consent of the Company.

The company is independent from Akome and each of its shareholders. The Acquisition will not constitute a fundamental change to the Company and will not result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Stock Exchange.

About Core One Labs Inc.

Core One is a life science biotechnology and technology research company focused on commercializing psychedelic drugs through novel delivery systems and assisted psychedelic psychotherapy. Core One has developed a patent-pending thin-film oral tape (the “TechnologyWhich dissolves instantly when placed in the mouth and delivers organic molecules in precise amounts into the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also has an interest in medical clinics which maintain a combined database of over 275,000 patients. Thanks to these clinics, the integration of its intellectual property, the R&D related to psychedelic treatments and new pharmacotherapies, the Company intends to obtain research regulatory approval for the advancement of treatments derived from psychedelics for mental health disorders. .

Core One Labs Inc.
Joel shacker
Chief executive officer



The Canadian Stock Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the contents of this press release.

The information contained in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect the current estimates, beliefs, intentions and expectations of management. These are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the control of the Company. These factors include, among others: risks and uncertainties associated with the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the company does not undertake to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and possession of substances under Controlled Drugs and Substances Act (Canada) without prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement in the illegal sale, production or distribution of psychedelics in the jurisdictions in which it operates. While Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate legalizing psychedelics for recreational purposes. Core One does not deal with psychedelics except in clinical and laboratory trials conducted under approved regulatory frameworks.

3 at-2027.html

Source link

]]> 0
All-State Academic: Central Region Sun, 25 Apr 2021 07:58:10 +0000 Lucy brooner Ankeny ACT Score: 34 GPA: 4.423 University: Undecided Major: Biomedical genius What are your life goals? The scientific world has always been a huge area of ​​interest for me. In 2019, I started scuba diving training, becoming a certified open water diver, and I hope to continue scuba diving throughout my life. I […]]]>

Lucy brooner


ACT Score: 34

GPA: 4.423

University: Undecided

Major: Biomedical genius

What are your life goals? The scientific world has always been a huge area of ​​interest for me. In 2019, I started scuba diving training, becoming a certified open water diver, and I hope to continue scuba diving throughout my life. I would love to train for even more certifications like night diving and dry suit diving in the future. I currently want to specialize in biomedical engineering, although I don’t know where. I would love to pursue a career in medical research and have often considered becoming a doctor myself. I want to help as many people as possible, whether I’m working with them directly as a doctor or indirectly doing behind-the-scenes research. My ultimate career goal is simply to be satisfied with my job and to enjoy working in my field.

Source link

]]> 0